Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kurt Huber

Showing results (31-40 of 752) with videos related to

Pageof 76
Sort By:
Thrombosis and Haemostasis|December 21, 2005
Circulating B-type natriuretic peptides in patients with acute coronary syndromes. Pathophysiological, prognostical and therapeutical considerationsRudolf Jarai, Johann Wojta, Kurt Huber
European Heart Journal Open|March 21, 2024
The use of mechanical circulatory support in elective high-risk percutaneous coronary interventions: a literature-based reviewAlexander Geppert, Kambis Mashayekhi, Kurt Huber
Vascular Pharmacology|December 27, 2011
Vascular effects of glycoprotein130 ligands--part I: pathophysiological roleSvitlana Demyanets, Kurt Huber, Johann Wojta
Nature Clinical Practice. Cardiovascular Medicine|September 18, 2008
A European perspective on improving acute systems of care in STEMI: we know what to do, but how can we do it?Keith A A Fox, Kurt Huber
Expert Opinion on Therapeutic Targets|August 22, 2009
Pigment epithelium-derived factor (PEDF) as a therapeutic target in cardiovascular diseaseKathrin Rychli, Kurt Huber, Johann Wojta
Biomarkers in Medicine|February 16, 2011
Functional testing methods for the antiplatelet effects of aspirinKarsten Schrör, Kurt Huber, Thomas Hohlfeld
Thrombosis and Haemostasis|June 8, 2013
Differences between ACC/AHA and ESC Guidelines on antiplatelet therapy in patients with acute coronary syndromesKurt Huber, Gregory Y H Lip
Journal of the American College of Cardiology|November 3, 2004
N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery diseaseRudolf Jarai, Robert Jarai, Kurt Huber
Current Pharmaceutical Design|December 2, 2014
Infection-associated biomarkers of inflammation in atherosclerosisEmil Kozarov, Kurt Huber, Johann Wojta
JAMA Cardiology|January 5, 2022
Sex Difference in Bleeding Risk With P2Y12 Inhibitor Agents After Percutaneous Coronary Intervention-ReplyBirgit Vogel, Kurt Huber, Roxana Mehran
Pageof 76

Showing results (31-40 of 752) with videos related to

Sort By:
Pageof 76
Thrombosis and Haemostasis|December 21, 2005
Circulating B-type natriuretic peptides in patients with acute coronary syndromes. Pathophysiological, prognostical and therapeutical considerationsRudolf Jarai, Johann Wojta, Kurt Huber
European Heart Journal Open|March 21, 2024
The use of mechanical circulatory support in elective high-risk percutaneous coronary interventions: a literature-based reviewAlexander Geppert, Kambis Mashayekhi, Kurt Huber
Vascular Pharmacology|December 27, 2011
Vascular effects of glycoprotein130 ligands--part I: pathophysiological roleSvitlana Demyanets, Kurt Huber, Johann Wojta
Nature Clinical Practice. Cardiovascular Medicine|September 18, 2008
A European perspective on improving acute systems of care in STEMI: we know what to do, but how can we do it?Keith A A Fox, Kurt Huber
Expert Opinion on Therapeutic Targets|August 22, 2009
Pigment epithelium-derived factor (PEDF) as a therapeutic target in cardiovascular diseaseKathrin Rychli, Kurt Huber, Johann Wojta
Biomarkers in Medicine|February 16, 2011
Functional testing methods for the antiplatelet effects of aspirinKarsten Schrör, Kurt Huber, Thomas Hohlfeld
Thrombosis and Haemostasis|June 8, 2013
Differences between ACC/AHA and ESC Guidelines on antiplatelet therapy in patients with acute coronary syndromesKurt Huber, Gregory Y H Lip
Journal of the American College of Cardiology|November 3, 2004
N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery diseaseRudolf Jarai, Robert Jarai, Kurt Huber
Current Pharmaceutical Design|December 2, 2014
Infection-associated biomarkers of inflammation in atherosclerosisEmil Kozarov, Kurt Huber, Johann Wojta
JAMA Cardiology|January 5, 2022
Sex Difference in Bleeding Risk With P2Y12 Inhibitor Agents After Percutaneous Coronary Intervention-ReplyBirgit Vogel, Kurt Huber, Roxana Mehran
Pageof 76